Aravive, Inc. Stock
Aravive, Inc. Stock
The community is currently still undecided about Aravive, Inc. with 1 Buy predictions and 0 Sell predictions.
With a target price of 16 € there is potential for a 49130.77% increase which would mean more than doubling the current price of 0.03 € for Aravive, Inc..
So far the community has only identified positive things for Aravive, Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Aravive, Inc. in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Aravive, Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Aravive, Inc. | - | - | - | - | - | - | - |
| Evolus Inc | 2.610% | 2.609% | 0.000% | 44.785% | 30.387% | 26.203% | - |
| Ardelyx Inc. | 3.070% | 1.608% | 0.032% | 93.211% | 9.308% | 11.823% | - |
| Salarius Pharmaceuticals Inc. | - | -3.015% | -16.087% | -67.833% | -30.450% | -98.515% | -99.994% |
Comments
Aravive, Inc. (NASDAQ: ARAV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $18.00 price target on the stock.
Show more
Ratings data for ARAV provided by MarketBeat